Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phototoxicity Test of Dapsone Gel
NCT02108483Phase 1Completed
- Sponsor
- Almirall
- Start
- Apr 2014
- Primary completion
- May 2014
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, double-blind, single-arm trial of dapsone in acne vulgaris, sponsored by Almirall. Primary endpoint: Phototoxicity Irritation Potential Using a Visual Scale at 4 Days. Started Apr 2014; status: completed.
02
Drugs
dapsone
03
Conditions
acne vulgaris
Beyond the preview
Go deeper on NCT02108483.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02108483.